Syndrome News and Research

RSS

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

24 Feb 2021

A new combination therapy for treating rare, fatal Sanfilippo syndrome in children

A study aiming to develop a new therapeutic technique could bring a revolution in our approach to treating rare, fatal Sanfilippo syndrome, a disorder that affects children as young as 2 years old and leads to childhood dementia and premature death.

24 Feb 2021

Household odorant smell tests could help detect COVID-19, say study

Researchers at the Weizmann Institute of Science and other institutions developed a new tool to help detect COVID-19 infection. The team developed and tested a real-time tool to measure olfactory perception impairment by asking the participants to smell household odorants.

24 Feb 2021

COVID-19 hospitalizations still high in England despite recent decline in cases, says study

Results from the latest round of the real-time assessment of community transmission study (REACT-1) study in England indicate that although coronavirus disease 2019 (COVID-19) cases have decreased, the number of hospitalizations remains high.

24 Feb 2021

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Researchers investigated the significance of a transmembrane glycoprotein basigin, or CD147, as a host cell co-receptor required for the entry of SARS-CoV-2. The findings reveal that recombinant human basigin does not interact with full-length spike protein or spike RBD of SARS-CoV-2.

24 Feb 2021

UK and South African SARS-CoV-2 variants show higher binding affinity to host cell receptor

New research by a team of scientists at Stanford University School of Medicine in the U.S. found that both the UK and South African SARS-CoV-2 variants display tighter binding to the ACE2 receptor.

24 Feb 2021

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

Researchers at Erasmus University Medical Center in The Netherlands have explored how and why new variants of SARS-CoV-2 have exhibited heightened infectivity.

24 Feb 2021

Corticosteroid receptor inhibitor shows anti-SARS-CoV-2 activity in vivo

A team of researchers examined PT150, which is an allosteric modulator of androgen and glucocorticoid receptors, to assess whether it had any antiviral activity or immunomodulatory activity to decrease the hyperinflammatory response of SARS-CoV-2 infection.

24 Feb 2021

Hyperactive immune system contributes to COVID-19 severity, lung damage

Researchers have pinpointed a helper T cell population in the lungs of patients with severe COVID-19 that may be central to the development of hyperinflammation, lung injury, and subsequent acute respiratory distress syndrome (ARDS) during disease.

24 Feb 2021

COVID-19 may alter host proteins to cause autoimmunity

To better understand the transient and chronic autoimmune symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, researchers from Memorial Sloan Kettering Cancer Center, Guizhou Medical University, and biotech company Curandis embarked on an endeavor to establish a comprehensive autoantigenome for COVID19.

23 Feb 2021

Sheep model may help address fertility problems in women

A Texas A&M AgriLife study with sheep may soon help address fertility problems in women, if it can discover ways to break the chain of generational transfer of polycystic ovary syndrome, PCOS -- one of the most common infertility disorders.

23 Feb 2021

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19

A new preprint research paper posted to the bioRxiv server reports the rapid emergence of variants within an infected individual. The evolution of the virus within an infected host is not excluded by the close similarity between the consensus sequences of single-person SARS-CoV-2, since the number of viral copies is at its peak soon after infection occurs and before the host develops adaptive immunity.

23 Feb 2021

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

By analyzing the cryoEM structures of antibodies against the SARS-CoV-2 virus, researchers report that the neutralizing capabilities of two antibodies are not affected by new strains as these antibodies target regions of the virus away from the ACE2 binding regions.

23 Feb 2021

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.

23 Feb 2021

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

A paper recently uploaded to the preprint server bioRxiv by researchers at Chapman University in California (Feb 22nd, 2021) utilized computational methods to screen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants for affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and monoclonal antibodies REG10987 and REG10933.

23 Feb 2021

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

GSK-3 inhibitors show promise in treating coronavirus infections

Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Feb 2021

Glycan switch may explain why SARS-CoV-2 causes such variable symptoms

Researchers in Portugal have provided evidence that might explain why infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes mild or even asymptomatic illness in some individuals, but severe coronavirus disease 2019 (COVID-19) in others.

23 Feb 2021

Researchers develop nanoceutical mask fabric that prevents SARS-CoV-2 transmission

Researchers at S N Bose National Centre for Basic Sciences in West Bengal found that a nanoceutical fabric, which is comfortable, washable, and anti-microbial, can prevent the transmission of SARS-CoV-2.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

Syndrome News and Research

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

A new combination therapy for treating rare, fatal Sanfilippo syndrome in children

Household odorant smell tests could help detect COVID-19, say study

COVID-19 hospitalizations still high in England despite recent decline in cases, says study

Basigin does not facilitate SARS-CoV-2 entry, say researchers

UK and South African SARS-CoV-2 variants show higher binding affinity to host cell receptor

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

Corticosteroid receptor inhibitor shows anti-SARS-CoV-2 activity in vivo

Hyperactive immune system contributes to COVID-19 severity, lung damage

COVID-19 may alter host proteins to cause autoimmunity

Sheep model may help address fertility problems in women

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

GSK-3 inhibitors show promise in treating coronavirus infections

Glycan switch may explain why SARS-CoV-2 causes such variable symptoms

Researchers develop nanoceutical mask fabric that prevents SARS-CoV-2 transmission

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News